The HCT/P Modernization Act of 2025This bill requires the Food and Drug Administration (FDA) to provide information to stakeholders and report on the regulation of human cell and tissue products, also referred to as human cells, tissues, or cellular or tissue-based products (HCT/Ps), which are articles containing or consisting of human cells or tissues that are intended for use in a human recipient.The bill requires the FDA to conduct workshops to educate stakeholders and facilitate discussion with them on advancing the science and regulation of human cell and tissue products. The FDA must establish a public docket to receive written comments on this topic, and submit to Congress a report with recommendations on regulating these products. Additionally, the bill requires the FDA to publish on its website educational materials about the Tissue Reference Group and best practices for obtaining a recommendation about products from them. Also, annually for three years, the FDA must publish on its website information on the inquiries submitted and average response times for the Tissue Reference Group, as well as the number of human cell and tissue manufacturers that have registered with the FDA and the number of inspections the FDA has conducted with respect to these manufacturers since 2019. (The Tissue Reference Group is a working group within the FDA that receives product-specific questions from, and provides recommendations for, stakeholders on the regulation of human cell and tissue products under the FDA’s rules.)
HB340, the HCT/P Modernization Act of 2025, would direct the Secretary of Health and Human Services, acting through the FDA, to take several steps aimed at improving transparency and streamlining oversight of human cell and tissue products (HCT/Ps). The bill requires the FDA to publish educational materials about the Tissue Reference Group and best practices for obtaining timely recommendations, and to provide public information on registrations, inspections, inquiries, and response times related to HCT/P establishments.
The bill also directs the FDA to expand stakeholder education through workshops and other interactive sessions for industry, tissue establishments, academic health centers, biomedical consortia, research organizations, and patients. It amends a provision of the Food and Drug Omnibus Reform Act of 2022 to update the scientific and regulatory topics covered in FDA best-practices guidance, and it requires the agency to open a public docket for comments on modernizing HCT/P regulation, including issues such as minimal manipulation and homologous use. Finally, the Secretary must report to Congress by September 30, 2026, summarizing workshop and docket input and making recommendations on how to regulate these products while balancing regulatory burden, scientific developments, access, and public health.
In practical terms, the bill would not directly rewrite the FDA’s core HCT/P regulatory framework, but it would add reporting, outreach, and process requirements that could influence how the agency administers existing rules under 21 CFR Part 1271 and section 361 of the Public Health Service Act. It would also increase public visibility into FDA oversight activity and the performance of the Tissue Reference Group, which may affect manufacturers, researchers, and clinicians working with stem cell and other cellular therapies.
The general sentiment reflected in the bill text and context is supportive of modernization, transparency, and regulatory predictability. The measure is framed as a way to help scientific advancement and improve access while still protecting public health, and it was introduced by bipartisan sponsors. No votes or committee debate are provided, so there is no recorded opposition in the supplied materials.
The main points of potential contention are likely to center on how far FDA should go in easing or clarifying oversight of HCT/Ps, especially around the definitions of minimal manipulation and homologous use, and whether changes could either reduce unnecessary regulatory burden or weaken safeguards. Stakeholders such as industry, patient advocates, academic researchers, and public health regulators may differ on the appropriate balance between faster access to therapies and maintaining strong safety standards.
The bill would primarily affect FDA administrative practices and guidance rather than directly changing the statutory definitions governing HCT/Ps. It would require new public reporting, educational outreach, workshops, a public comment docket, and a congressional report, while also updating an existing FDA best-practices provision in the Food and Drug Omnibus Reform Act of 2022. These requirements would increase transparency for tissue establishments, manufacturers, and other stakeholders and could shape future interpretation and enforcement of 21 CFR Part 1271 and related Public Health Service Act provisions.
The available context suggests a generally favorable and reform-oriented sentiment. The bill is presented as a modernization measure intended to improve regulatory predictability, scientific communication, and access to human cell and tissue products while preserving public health protections. Because no committee transcript or vote data were provided, there is no recorded floor or committee opposition in the supplied materials, but the structure of the bill indicates an effort to build consensus among FDA, industry, researchers, and patients.
Likely areas of contention involve the scope and pace of FDA oversight reform. Some stakeholders may argue the bill does not go far enough to reduce regulatory barriers and speed access to stem cell and other cellular therapies, while others may worry that modernization efforts could loosen standards for minimal manipulation, homologous use, or product classification in ways that could compromise safety. The bill’s emphasis on public reporting and stakeholder engagement suggests an attempt to address these tensions, but the balance between innovation, access, and public health remains the central policy dispute.